Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989177 | 0.90 | CA12 (0.42) | SCN4AMEN1KMT2AALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL7809921 | 0.88 | CA12 (0.41) | SCN4AMEN1KMT2AALDH1A1MAPT | |
| Water SCHEMBL28192673 | 0.88 | CA12 (0.41) | SCN4AMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL13978567 | 0.88 | SCN4A (0.41) | SCN4AMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3138342 | 0.83 | MAPT (0.52) | SCN4AMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL3364770 | 0.83 | NPC1 (0.50) | SCN4ANPC1RAB9A | |
| SCHEMBL6774958 | 0.82 | SCN4A (0.43) | SCN4AALDH1A1MAPTSCN9AGAA | |
| SCHEMBL6779530 | 0.82 | SCN4A (0.52) | SCN4ASCN9A | |
| SCHEMBL28078120 | 0.82 | MEN1 (0.53) | MEN1KMT2AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL15418939 | 0.82 | PARP10 (0.45) | SCN4AMEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4832647-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | claimed |
| EP-1173169-B1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | claimed |
| EP-1173169-A4 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2007-04-04 | — | — | EP | claimed |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | EURO-CELTIQUE S.A. | 2003-04-10 | — | — | US | claimed |
| JP-2002540155-A | — | — | 2002-11-26 | — | — | JP | claimed |
| US-6414011-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2002-07-02 | — | — | US | claimed |
| EP-1173169-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-23 | — | — | EP | claimed |
| WO-2000057877-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-05 | — | — | WO | claimed |
| CN-105408334-A | Substituted pyrazolopyrimidines as kinases inhibitors | JIANGSU MEDOLUTION LTD | 2016-03-16 | — | — | CN | disclosed |
| CN-104844609-A | Double-site irreversible Brutons tyrosine kinase inhibitor | HANGZHOU HERTZ PHARMACEUTICAL CO LTD | 2015-08-19 | — | — | CN | disclosed |
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | disclosed |
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | disclosed |
| EP-1292577-B1 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO CELTIQUE SA (LU) | 2012-10-24 | — | — | EP | disclosed |
| EP-1292577-A2 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | Euro-Celtique S.A. (LU) | 2003-03-19 | — | — | EP | disclosed |
| US-6414011-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2002-07-02 | — | — | US | disclosed |
| EP-1173169-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-23 | — | — | EP | disclosed |
| US-20020006947-A1 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | PURDUE PHARMA L.P. | 2002-01-17 | — | — | US | disclosed |
| WO-2001072714-A2 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO-CELTIQUE S.A. (LU) | 2001-10-04 | — | — | WO | disclosed |
| WO-2000057877-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | GRIK5, GRIN3A, GRIK3 | SCN4A 598/4885MEN1 4828/4885KMT2A 4141/4885 |
| US-20020006947-A1 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | GRIK5, CACNA1I, SOD1 | SCN4A 621/4885MEN1 4816/4885KMT2A 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.